The week in health tech, explained in plain English.Get the free newsletter →
June 11, 2026

Takeaways from the most recent news in the technology and policies shaping healthcare.

Finance

GSK Buys Nuvalent for $10.6B to Add Two Lung Cancer Drugs

By Healthcare Technology News ·

GSK is paying $10.6 billion to acquire Nuvalent, a biotech with two lead drugs aimed at non-small cell lung cancer (NSCLC), MedCity News reports. Both programs are under FDA review, and GSK says it plans to launch them this year if they win approval.

The two drugs target different driver mutations in NSCLC, the most common form of lung cancer. Precision oncology agents like these treat tumors defined by specific genetic alterations rather than by where the cancer originates, a strategy that has reshaped how late-stage lung cancer is managed. Nuvalent designed its candidates to overcome resistance and reach the brain, common weaknesses of earlier targeted therapies.

The deal continues a wave of large pharma buying late-stage oncology assets to refill pipelines ahead of looming patent expirations. For GSK, acquiring near-commercial drugs shortens the path to revenue and deepens its bet on targeted cancer treatment, a market where rivals including AstraZeneca and Pfizer are aggressively competing.

Sources

More in Finance

Finance

AstraZeneca GLP-1 Pill Shows Promise in Obesity Trials

AstraZeneca's oral GLP-1 drug showed promise in mid-stage obesity and diabetes trials, but its standing against rival pills remains unclear.

Why it matters: An effective GLP-1 pill could broaden access to weight-loss and diabetes treatment and intensify competition in a market headed past $100 billion.

Finance

Incyte Pays $1.25B for Vega and Its Bleeding Disorder Drug

Incyte is acquiring Vega Therapeutics for $1.25 billion to gain a late-stage von Willebrand disease drug as patent expiration looms for its top product, Jakafi.

Why it matters: The deal shows how biopharma companies race to backfill pipelines and diversify ahead of major patent cliffs.

Finance

GSK to Buy Cancer Drugmaker Nuvalent for $10.6 Billion

GSK is acquiring Nuvalent for $10.6 billion to add late-stage targeted lung cancer drugs, the latest in a run of biopharma deals.

Why it matters: The deal shows how big drugmakers are spending billions on precision oncology to refill pipelines ahead of patent cliffs.